Bioreliance corp:1108045 [14-026676]
Ended Awarded
- Contract number
- HHSN26100002
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,218
Award facts
- Contract value 100% obligated
- $3,218.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
About this award
Bioreliance Corporation, a Life Sciences Services division of Sigma-Aldrich Corporation, received a Blanket Purchase Agreement (BPA) call award from the National Cancer Institute on March 13, 2014, with a ceiling value of $3,218. The contract, which was not set aside for any specific business category, was awarded on a firm fixed-price basis for performance in Bethesda, Maryland, with an ultimate completion date of April 30, 2014. As a subsidiary of Sigma-Aldrich Corporation, Bioreliance brought its specialized expertise in laboratory and testing services to support the National Cancer Institute's research initiatives.
Bioreliance Corporation specializes in providing critical microbiological and scientific testing services essential to pharmaceutical and biotechnology research, including endotoxin testing, sterility testing, and Limulus Amebocyte Lysate (LAL) testing. The company has established itself as a key service provider to federal health research institutions, with experience supporting vaccine development, investigational new drug application processes, and various research initiatives across agencies including the National Institutes of Health and the Centers for Disease Control and Prevention. This BPA call represents the contractor's continued engagement with federal agencies requiring specialized testing capabilities to support their research missions.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on March 13, 2014.
How much is contract HHSN26100002 worth?
The government has obligated $3,218 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a BPA call under HHSN263199800048997B, a blanket purchase agreement.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award